Leukotriene D4: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction - PubMed (original) (raw)

Leukotriene D4: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction

F Michelassi et al. Science. 1982.

Abstract

Leukotriene D4 (2 c 10(-9) mole), injected into the left circumflex coronary artery of anesthetized sheep, produced profound coronary vasoconstriction and impaired regional ventricular wall motion. This cardiac effect was neither inhibited by prior treatment of the sheep with a cyclooxygenase inhibitor nor associated with thromboxane B2 release into the coronary sinus. Intravenous FPL 55712 completely abolished the coronary vasoconstriction of leukotriene D4, but a significant reduction of regional wall shortening persisted.

PubMed Disclaimer

Similar articles

• Leukotriene D4: a potent sheep coronary vasoconstrictor not blocked by ibuprofen.
  Michelassi F, Landa L, Hill RD, Huttemeier P, Lowenstein E, Zapol WM, Watkins WD. Michelassi F, et al. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:397-9. Adv Prostaglandin Thromboxane Leukot Res. 1983. PMID: 6221552 No abstract available.
• Effects of leukotrienes B4 and C4 on coronary circulation and myocardial contractility.
  Michelassi F, Castorena G, Hill RD, Lowenstein E, Watkins WD, Petkau AJ, Zapol WM. Michelassi F, et al. Surgery. 1983 Aug;94(2):267-75. Surgery. 1983. PMID: 6308844
• Inhibition of leukotriene D4-induced coronary vasoconstriction by leukotriene antagonists in the anesthetized dog.
  Kopia GA, Valocik RE, Torphy TJ, Cieslinksi LB, Sarau HM, Foley JJ, Wasserman MA. Kopia GA, et al. J Pharmacol Exp Ther. 1987 Apr;241(1):174-80. J Pharmacol Exp Ther. 1987. PMID: 2437287
• Comparison of cardiac and hemodynamic effects of platelet-activating factor-acether and leukotriene D4 in anesthetized dogs.
  Fiedler VB, Mardin M, Abram TS. Fiedler VB, et al. Basic Res Cardiol. 1987 Mar-Apr;82(2):197-208. doi: 10.1007/BF01907067. Basic Res Cardiol. 1987. PMID: 3606544
• [Leukotrienes and the cardiovascular system].
  Sagach VF. Sagach VF. Patol Fiziol Eksp Ter. 1986 Jan-Feb;(1):84-9. Patol Fiziol Eksp Ter. 1986. PMID: 3010220 Review. Russian. No abstract available.

Cited by

• Inflammatory Mediators in Atherosclerotic Vascular Remodeling.
  Evans BR, Yerly A, van der Vorst EPC, Baumgartner I, Bernhard SM, Schindewolf M, Döring Y. Evans BR, et al. Front Cardiovasc Med. 2022 May 4;9:868934. doi: 10.3389/fcvm.2022.868934. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35600479 Free PMC article. Review.
• Leukotriene receptors as potential therapeutic targets.
  Yokomizo T, Nakamura M, Shimizu T. Yokomizo T, et al. J Clin Invest. 2018 Jul 2;128(7):2691-2701. doi: 10.1172/JCI97946. Epub 2018 May 14. J Clin Invest. 2018. PMID: 29757196 Free PMC article. Review.
• The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.
  Hoxha M, Rovati GE, Cavanillas AB. Hoxha M, et al. Eur J Clin Pharmacol. 2017 Jul;73(7):799-809. doi: 10.1007/s00228-017-2242-2. Epub 2017 Apr 4. Eur J Clin Pharmacol. 2017. PMID: 28374082 Review.
• A case of Kounis syndrome after a hornet sting and literature review.
  Ralapanawa DM, Kularatne SA. Ralapanawa DM, et al. BMC Res Notes. 2014 Dec 3;7:867. doi: 10.1186/1756-0500-7-867. BMC Res Notes. 2014. PMID: 25465208 Free PMC article. Review.
• Indirubin-3'-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration.
  Blazevic T, Schaible AM, Weinhäupl K, Schachner D, Nikels F, Weinigel C, Barz D, Atanasov AG, Pergola C, Werz O, Dirsch VM, Heiss EH. Blazevic T, et al. Cardiovasc Res. 2014 Mar 1;101(3):522-32. doi: 10.1093/cvr/cvt339. Epub 2013 Dec 23. Cardiovasc Res. 2014. PMID: 24368834 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database